Enovis Corporation (NYSE:ENOV) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lessened its stake in Enovis Corporation (NYSE:ENOV) by 14.6% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,515 shares of the company’s stock after selling 1,454 shares during the period. Assenagon Asset Management S.A.’s holdings in Enovis were worth $325,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in ENOV. Quadrant Capital Group LLC grew its holdings in Enovis by 53.0% during the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company’s stock worth $30,000 after acquiring an additional 239 shares during the period. Amalgamated Bank grew its holdings in Enovis by 1.0% during the fourth quarter. Amalgamated Bank now owns 25,887 shares of the company’s stock worth $1,136,000 after acquiring an additional 264 shares during the period. California State Teachers Retirement System grew its holdings in Enovis by 0.7% during the fourth quarter. California State Teachers Retirement System now owns 52,236 shares of the company’s stock worth $2,292,000 after acquiring an additional 350 shares during the period. Arizona State Retirement System grew its holdings in Enovis by 2.6% during the fourth quarter. Arizona State Retirement System now owns 16,208 shares of the company’s stock worth $711,000 after acquiring an additional 414 shares during the period. Finally, New York State Teachers Retirement System grew its holdings in Enovis by 3.5% during the fourth quarter. New York State Teachers Retirement System now owns 13,538 shares of the company’s stock worth $594,000 after acquiring an additional 457 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Stock Performance

ENOV opened at $30.69 on Friday. The stock has a market cap of $1.75 billion, a P/E ratio of -2.20 and a beta of 1.71. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.55 and a quick ratio of 1.32. The stock’s 50 day simple moving average is $33.11 and its 200 day simple moving average is $39.11. Enovis Corporation has a 1-year low of $29.13 and a 1-year high of $49.83.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.07. Enovis had a positive return on equity of 5.99% and a negative net margin of 37.65%. The firm had revenue of $558.83 million for the quarter, compared to analyst estimates of $558.80 million. During the same quarter in the prior year, the company earned $0.50 EPS. Enovis’s revenue was up 8.2% on a year-over-year basis. As a group, equities analysts anticipate that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Analyst Ratings Changes

ENOV has been the topic of a number of recent analyst reports. JMP Securities dropped their price objective on Enovis from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Friday, May 9th. Needham & Company LLC lowered their price target on Enovis from $64.00 to $57.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Finally, Canaccord Genuity Group lowered their price target on Enovis from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $58.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.